Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Not Applicable

• Conditions: Type 2 Diabetes; Obesity; Nesfatin-1; Insulin Resistance

• Registration Number: NCT04298515
• Lead Sponsor: Istanbul Medeniyet University

Brief Summary

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Detailed Description

Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Study Timeline

• Status Verified: 2020-02
• Study First Submitted: 2020-02-10
• Study Start: 2020-03-02
• Study First Submitted QC: 2020-03-05
• Last Update Submitted: 2020-03-05
• Study First Posted: 2020-03-06
• Last Update Posted: 2020-03-06
• Primary Completion: 2021-03-31
• Study Completion: 2021-03-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Type 2 diabetes
• Insulin resistance
• Obesity disease

Exclusion Criteria

• Pediatric individuals
• All patients who are hospitalized,
• Liver disease
• Cancer patients
• Disease related to the gastrointestinal tract
• Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
• Neurological disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Nefratin-1 in obesity	1 day (Blood will be drawn from patients once)	Blood will be drawn from obesity patients after 12 hours of fasting (n=45)
Nefratin-1 in insulin resistance	1 day (Blood will be drawn from patients once)	Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)
Nefratin-1 in type 2 diabetes	1 day (Blood will be drawn from patients once)	Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)

Trial Locations

Locations (1)

Haydarpaşa Numune Education and Research Hospital; 🇹🇷 İstanbul, Turkey